Written by Steven Hansen
The U.S. new cases 7-day rolling average is 6.1 % LOWER than the 7-day rolling average one week ago. U.S. deaths due to coronavirus are now 4.4 % LOWER than the rolling average one week ago. U.S. hospitalizations due to COVID-19 are now 10.0 % HIGHER than the rolling average one week ago. Today’s posts include:
- U.S. Coronavirus New Cases are at an elevated 138,903
- U.S. Coronavirus deaths are at 826
- U.S. Coronavirus hospitalizations are at a record 93,238
- The 7-day rolling average rate of Growth of the Pandemic shows new cases improved, hospitalizations improved, and deaths improved [note that there is usually under-reporting over holiday periods and over-reporting for days after the holiday ends – so I would wait to mid-week to validate there was really an improvement]
- ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19
- World’s Biggest Vaccine Producer Lends Support to AstraZeneca After Drugmaker Misstep
- Wearing A Mask With A Exhale Valve Is Worthless In Preventing COVID Spread
- 265 million people are expected to be thrown into severe food insecurity as a result of lockdowns
- AstraZeneca CEO Says Co Likely to Run New Global Trial on COVID-19 Vaccine
- Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the coming weeks
- Fauci Warns Of ‘Surge Upon A Surge’ As COVID-19 Hospitalizations Hit Yet Another High
- American mink have coronavirus, but there’s no sign yet of them passing it to humans
The recent worsening of the trendlines for new cases should be attributed to going back to college/university, cooler weather causing more indoor activities, possible mutation of the virus, fatigue from wearing masks / social distancing, holiday activities, political rallies / voting, and continued loosening of regulations designed to slow the coronavirus spread.
My continuing advice is to continue to wash your hands (especially after using the toilet as COVID first sheds in your stool), putting down the toilet seat (as flushing the toilet releases a plume), wear masks, avoid crowds, and maintain social distancing. No handwashing, mask, or social distancing will guarantee you do not get infected – but it sure as hell lowers the risk in all situations – and the evidence to-date shows a lower severity of COVID-19. In addition, certain activities are believed to carry a higher risk – like being inside in air conditioning and removing your mask (such as restaurants, around your children/grandchildren, bars, and gyms). It is all about viral load – and outdoor activities are generally safe if you can maintain social distance.
include($_SERVER[‘DOCUMENT_ROOT’].’/pages/coronavirus1.htm’); ?>
Hospitalizations (grey line) and Mortality (green line) For Week ending 14NOV2020
source: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
The Seven Day Rolling Average Rate of growth of pandemic new cases improved, hospitalizations improved, and deaths improved
Too many headlines are telling you the pandemic is out of control. Anyone with analytical abilities knows this is not true. For this to be true, the rate of growth needs to continue to rise.
No doubt, the pandemic is elevated and we must take steps to minimize our exposure to the virus.
The graph below shows the rate of growth relative to the growth a week earlier updated through today. As one can see, the rate of growth for new cases peaked over one month ago and the rate of growth has been decelerating.
This graph demonstrates that the recent actions to contain the pandemic are beginning to bite. In the scheme of things, new cases decline first, followed by hospitalizations, and then deaths.
It is up to each of our readers to protect themselves and others by washing your hands, wearing a mask, avoiding crowds, and maintaining social distancing.
Coronavirus News You May Have Missed
The State of American Restaurants, by City: The Catastrophe of the Second Wave – Wolf Street
The second wave of the Pandemic is gripping the restaurant business that had already been battered by the first wave. Given the exploding infection rates across the US, restaurants had to dial back their services, and in a number of cities even outdoor dining is now off-limits. And in many cities where it’s not off-limits, the winter weather makes it very difficult, despite the conceptually dubious indoorification of outdoor dining, with sidewalk buildings fashioned of plastic sheets, plexiglass, wood, and steel.
The number of “seated diners,” a daily measure OpenTable provides to track walk-ins and diners with reservations, has been dropping since the end of October, compared to the same weekday in the same week last year. At the end of October, the seven-day moving average of the number of seated diners across the US was down 40% from a year earlier. For the seven days through November 28, the number of seated diners was down by 56%, the lowest since early August. The reading of “-100%” in April, meaning essentially no seated diners due to the lockdowns, is once again playing out in some cities, and we’ll get to them in a moment:
World’s Biggest Vaccine Producer Lends Support to AstraZeneca After Drugmaker Misstep – Yahoo
Serum Institute of India (SII), which has partnered with Novavax, Inc (NASDAQ: NVAX) and AstraZeneca Plc (NYSE: AZN) for trials in India, believes the latter’s COVID-19 vaccine is “a very good one.”
What Happened: SII Chief Executive Adar Poonawalla praised the efficiency of AstraZeneca’s vaccine, called Covishield, during an online press briefing on Saturday, Reuters has reported.
“What we found with Covishield in its global trial is there were zero hospitalizations, which means even if you do get infected you’re not going to have a severe attack and secondly even those who got the disease were not infecting others,” he explained during the call.
Poonawalla also said the institute would apply for an emergency-use license in the next couple of weeks.
SII is the world’s largest vaccine producer, according to Reuters.
Why It Matters: The Serum Institute is also conducting trials for the Novavax vaccine but says that AstraZeneca has a competitive advantage over the rest of pharma companies.
‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 – Science
Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says, far above what many vaccine scientists were expecting just a few weeks ago.
More impressive still, Moderna’s candidate had 100% efficacy against severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group. The company today plans to file a request for emergency use authorization (EUA) for its vaccine with the U.S. Food and Drug Administration (FDA), and is also seeking a similar green light from the European Medicines Agency.
The data released today bolster an interim report from the company two weeks ago that only analyzed 95 total cases but produced similarly impressive efficacy. “I would still like to see all of the actual data, but what we’ve seen so far is absolutely remarkable,” says Paul Offit, a vaccine researcher at the Children’s Hospital of Philadelphia who is a member of an independent committee of vaccine experts that advises FDA.
Moderna’s vaccine against SARS-CoV-2, the virus that causes COVID-19, relies on a novel technology that uses messenger RNA (mRNA) to code for a protein called spike that studs the surface of the pathogen. Pfizer and BioNTech have developed a similar mRNA vaccine against COVID-19 and also reported excellent results, with an efficacy of 95%, in the final analysis of their 45,000-person trial. In that study, which ended after 170 cases of COVID-19 were identified, only 10 severe cases occurred, and just one was in the vaccinated group.
[editor’s note: you may want to read this post completely Another interesting post: Moderna Designed a Covid-19 Vaccine in Just Two Days Thanks to mRNA Technology]
IF I’M WEARING A MASK WITH A VALVE ON IT, I’M NOT HELPING. – Inverse
The beauty of wearing a face mask is that it’s a one-two-punch that protects both the wearer and anyone they interact with by limiting the flow of potentially contagious particles through surgical fabric or cloth layers. But when it comes to masks with valves, Staymates says in a statement that they fulfill only one part of that equation.
“I don’t wear a mask to protect myself. I wear it to protect my neighbor, because I might be asymptomatic and spread the virus without even knowing it,” Staymates said. “But if I’m wearing a mask with a valve on it, I’m not helping.”
The problem with valves is that they were originally designed to be worn in situations where only protecting the wearer was important — like when sanding wood, for example — and limit incoming particles without filtering outgoing air.
This isn’t exactly news — in a mask-wearing FAQ on its website, the CDC recommends that N95 masks with ventilators be covered again with a surgical mask to prevent virus spread. But Staymates explains in his paper that he wanted to find a way to translate this crucial information to the public that was clear and palatable.
The Geopolitics of Vaccine Distribution – Geopolitical Futures
[editor’s note: this post deserves a full read. I have included two graphs and the conclusion from this post]
… The poorest nations are likeliest to get a coronavirus vaccine last. But there’s room for optimism as many other companies will continue developing coronavirus vaccines. Most, like the one made by AstraZeneca, will not require the extreme cold chain that Pfizer’s vaccine needs. In addition, AstraZeneca has pledged to forgo profits until the pandemic is over. The company is also working with nongovernmental organizations like the Bill & Melinda Gates Foundation to provide vaccines to developing countries.
The question about global vaccine distribution has therefore shifted from if to when. But will the vaccine(s) come in time to prevent further economic damage and social unrest? Vaccine delays could create or aggravate default risks in poorer countries, with financial contagion spreading to richer countries. Many people are no longer willing to tolerate lockdowns. All across Europe citizens are protesting additional safety measures, with demonstrations in Italy turning violent last week.
Ancillary effects of lockdowns have created other grievances against governments too. In many places, families and spouses have been separated because of border closures and arbitrary immigration policies. In Indonesia, for example, binational unmarried couples are not allowed to reunite, but elderly foreigners are allowed in as tourists despite the fact that elderly people are the likeliest to die from coronavirus. These policies have resulted in the Indonesian government being inundated with complaints by angry citizens. They reveal the tension between concerns over public health, the economy and the social fabric, and it’s not clear that they can be improved until a vaccine is fully deployed.
Indeed, few societies are willing to control the virus at the cost of ripping the social fabric. The coronavirus has revealed an immense tension between the economic and social pillars of our society. Governments have no good options. Some will be tempted to reimpose lockdowns, justifying them with the claim that they will be eased as soon as a vaccine is available. But this is a false reassurance. For citizens of rich countries, widespread vaccination is still months away. For citizens of poor countries, widespread vaccination may be years away. A restless public is not going to tolerate indefinite lockdowns through 2021, and governments that try to impose them should be prepared for civil unrest.
What No One Is Saying About The Lockdowns – ZeroHedge
Now those advocating for lockdowns have seen the destruction and death that those policies have wrought this year and we are living through that right now. Not only are people being deprived of their livelihoods and forced into grinding poverty as a direct result of these shutdowns, but now the undeniable truth is that if you are advocating for lockdowns, you are advocating for some portion of the population to be consigned to death.
This is no longer debatable. It is even openly admitted—although months too late by the World Health Organization.
DAVID NABARRO: I want to say it again: we in the World Health Organization do not advocate lockdowns as a primary means of control of this virus. [. . .] We may well have a doubling of world poverty by early next year. We may well have at least a doubling of child malnutrition because children are not getting meals at school and their parents and poor families are not able to afford it.
This is a terrible, ghastly global catastrophe, actually. And so we really do appeal to all world leaders: stop using lockdown as your primary control method. Develop better systems for doing it. Work together and learn from each other. But remember, lockdowns just have one consequence that you must never, ever belittle, and that is making poor people an awful lot poorer.
SOURCE: The Week in 60 Minutes #6
This is the point at which, no doubt, I’ll be expected to produce the data to back up the non-controversial observation that lockdowns kill, even though that data will do precisely nothing to penetrate the consciousness of those who have already decided that they occupy the moral high ground for advocating locking billions of people around the globe as prisoners inside their own homes. But persevere I will.
I’ll point, for example, to the letter signed by hundreds of doctors calling the lockdowns themselves a “mass casualty incident” and exhorting politicians to end the shutdowns.
I’ll point to the research that shows that thousands of people will die because of delays to cancer surgery treatments as a result of the medical shutdowns.
I’ll point to the research of the Well-Being Trust showing that 75,000 Americans are expected to die deaths of despair—including alcohol and drug misuse and suicide—this year alone as a result of the lockdowns.
I will point to the research of The Lancet showing that 265 million people are expected to be thrown into severe food insecurity as a result of these lockdowns.
I will even point to the research showing 125,000 children are expected to die from malnutrition as a result of these lockdowns.
Fauci Warns Of ‘Surge Upon A Surge’ As COVID-19 Hospitalizations Hit Yet Another High – NPR
Across the country, medical personnel are now bracing for what they fear will be a new wave of infections after millions of Americans ignored the advice of public health experts and traveled for the Thanksgiving holiday. Already, hospital resources are being stretched thin, with many institutions reporting a dire shortage of beds and personnel to handle the influx of new patients.
“We may see a surge upon a surge,” Dr. Anthony Fauci, the nation’s top infectious disease expert, told ABC’s This Week on Sunday. “We don’t want to frighten people, but that’s just the reality. We said that these things would happen as we got into the cold weather and as we began traveling, and they’ve happened.”
With the December holidays just around the corner and more people traveling, “it’s going to happen again,” Fauci said. “We’re getting into colder weather and an even larger holiday season.”
CMS Announces Comprehensive Strategy to Enhance Hospital Capacity Amid COVID-19 Surge – Centers For Medicare and Medicaid Services
Today, the Centers for Medicare & Medicaid Services (CMS) outlined unprecedented comprehensive steps to increase the capacity of the American health care system to provide care to patients outside a traditional hospital setting amid a rising number of coronavirus disease 2019 (COVID-19) hospitalizations across the country. These flexibilities include allowances for safe hospital care for eligible patients in their homes and updated staffing flexibility designed to allow ambulatory surgical centers (ASCs) to provide greater inpatient care when needed. Building on CMS’s previous actions to expand the availability of telehealth across the nation, these actions are aimed at allowing health care services to be provided outside a hospital setting while maintaining capacity to continue critical non-COVID-19 care, allowing hospitals to focus on the increased need for care stemming from public health emergency (PHE).
“We’re at a new level of crisis response with COVID-19 and CMS is leveraging the latest innovations and technology to help health care systems that are facing significant challenges to increase their capacity to make sure patients get the care they need,” said CMS Administrator Seema Verma. “With new areas across the country experiencing significant challenges to the capacity of their health care systems, our job is to make sure that CMS regulations are not standing in the way of patient care for COVID-19 and beyond.”
[editor’s note: for those on Medicare and Medicaid – this post is worth a full read]
AstraZeneca CEO Says Co Likely to Run New Global Trial on COVID-19 Vaccine – Medscape
AstraZeneca Plc is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine, according to the company’s Chief Executive Pascal Soriot, Bloomberg News reported on Thursday.
Instead of adding the trial arm to an ongoing U.S. process, a new trial would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca’s studies, the report said.
AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and EU regulatory approval.
Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
American mink have coronavirus, but there’s no sign yet of them passing it to humans. – New York Times
As coronavirus infections surge in people, the virus is also spreading in mink. Oregon reported its first cases at a mink farm this week with 10 infected animals but no deaths. Mink farms in Utah, Michigan and Wisconsin have also reported infections.
Six other countries have reported infected mink: the Netherlands, Denmark, Sweden, Italy, Spain and Greece. Some workers also were infected, as would be expected, because in most cases it is humans who pass the virus to farmed mink.
In the Netherlands and Denmark, genetic tests show that after humans passed the virus to mink, the mink passed it back again, with some mutations. No such mink-to-human transmission has been detected yet in the U.S., but scientists there and elsewhere are deeply concerned about the spread of the coronavirus to a variety of animals.
One of the mutations that arose in Denmark worried scientists, because it appeared in laboratory tests that this mutated version of the virus might be less well controlled by vaccines. However, no further evidence has supported that concern, and the variant in question hasn’t been found in people since September, according to Danish authorities.
… According to Fur Commission USA, an industry organization, about 275 U.S. mink farms produce about 3 million pelts a year. The Department of Agriculture has ordered quarantines of infected farms and testing, and has posted strict guidelines on movement of mink from farm to farm, but it has not ordered mass culls. Thousands of mink have apparently died from coronavirus infections at American farms.
The hurdles of distributing Covid vaccine to over 330 million people in the U.S. – CNBC
Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the coming weeks – Yahoo
Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November.
It is the second time that Novavax, which already has a late-stage UK trial underway, has rescheduled the Phase 3 trial after first flagging an October start, hampered by issues in scaling up its manufacturing.
Novavax plans to use vaccine material produced at commercial scale for the trial in the United States and Mexico and has been working closely with the U.S. Food and Drug Administration to greenlight the use of the vaccine made at a North Carolina plant.
The company also said it has completed enrollment for its 15,000 participant UK trial and expects interim data as soon as the first quarter of 2021.
It has previously said that the UK trial could be the basis for some global regulatory approvals.
More than 25% of enrollees in the UK trial are over the age of 65, while a large proportion of volunteers had underlying co-morbid medical conditions generally representative of the population.
Novavax is also running a fully enrolled Phase 2b trial in South Africa, which has 4,400 volunteers including 245 who are medically stable, HIV positive participants. Efficacy data from that trial could also be available in the first quarter of next year.
The following are foreign headlines with hyperlinks to the posts
An alleged serious “neurological and psychological” adverse reaction during AstraZeneca’s trial in India is under investigation in India.
A woman in Singapore who got SARS-CoV-2 while pregnant reportedly gave birth to a baby with antibodies against the virus.
Public gatherings limited to two people in Hong Kong
EU Seeks to Bypass Patents to Boost Drugs Access in Crises
Berlin Plans Six Vast COVID-19 Vaccination Centres Handling 4000 People a Day
English Tequila Bar Registers as a Church in Effort to Bypass U.K. COVID
Netanyahu warns Israel may have to return to tighter restrictions.
Australia hopes a pilot program for international students can restart its crucial education sector.
Strained hospitals reflect the virus’s wide reach in Turkey
Kim Jong Un is cutting off his economic lifeline, China, to stave off Covid-19
‘I thought I was going to die.’ Inside Venezuela’s mandatory quarantine motels
COVID-19 disruptions could result in up to 100,000 extra malaria deaths this year
The following are additional national and state headlines with hyperlinks to the posts
Full results with Moderna’s coronavirus vaccine indicate 94.1% efficacy in preventing symptomatic COVID-19 in a 30,000-person trial. The company said it will apply for emergency use authorization (EUA) today.
The vaccination campaign will pose a “mind-blowing” challenge for poor, rural states.
Pennsylvania state Sen. Doug Mastriano abruptly left a White House meeting with President Donald Trump after his rapid test for coronavirus came back positive.
New York City Schools Will Reopen With New COVID-19 Testing Protocol
Air travel on Sunday after Thanksgiving hits highest level since March
California sees record number of coronavirus hospitalizations
Employers Decide Whether to Report Healthcare Worker Deaths
Moderna CEO Says COVID Vaccine Ready to Roll Out Within Day of FDA Approval
Michigan Woman with COVID in Coma after Giving Birth to Twins a Month Early
U.S. Records More COVID Infections in a Single Day than Japan Has to Date
NYC to Reopen Elementary Schools After Being Closed for More Than a Week
New York is initiating emergency measures to help hospitals cope with what Gov. Andrew Cuomo called “a new phase in the war against Covid.”
NFL fines Saints and Patriots hundreds of thousands of dollars for Covid-19 violations
Rhode Island hospitals are full. Covid field hospital opening today.
Charlotte Hornets to kick off season with no fans
Coronavirus cases fell by roughly 30% during England’s lockdown
Today’s Posts On Econintersect Showing Impact Of The Pandemic With Hyperlinks
October 2020 Headline Pending Home Sales Declined
November 2020 Chicago Purchasing Managers Barometer Again Modestly Declines
November 2020 Texas Manufacturing Significantly Declined
November 2020 Chemical Activity Barometer Rises But Remains In Contraction
Warning to Readers
The amount of politically biased articles on the internet continues to increase. And studies and opinions of the experts continue to contradict other studies and expert opinions. Honestly, it is difficult to believe anything anymore. A study usually cannot establish cause and effect – but only correlation. Be very careful what you believe about this pandemic.
I assemble this coronavirus update daily – sifting through the posts on the internet. I try to avoid politically slanted posts (mostly from CNN, New York Times, and the Washington Post) and can usually find unslanted posts on that subject from other sources on the internet. I wait to publish posts on subjects that I cannot validate across several sources. But after all this extra work, I do not know if I have conveyed the REAL facts. It is my job to provide information so that you have the facts necessary – and then it is up to readers to draw conclusions.
Analyst Opinion of Coronavirus Data
There are several takeaways that need to be understood when viewing coronavirus statistical data:
- The global counts are suspect for a variety of reasons including political. Even the U.S. count has issues as it is possible that as much as half the population has had coronavirus and was asymptomatic. It would be a far better metric using a random sampling of the population weekly. In short, we do not understand the size of the error in the tracking numbers.
- Just because some of the methodology used in aggregating the data in the U.S. is flawed – as long as the flaw is uniformly applied – you establish a baseline. This is why it is dangerous to compare two countries as they likely use different methodologies to determine who has (and who died) from coronavirus.
- COVID-19 and the flu are different but can have similar symptoms. For sure, COVID-19 so far is much more deadly than the flu. [click here to compare symptoms]
- From an industrial engineering point of view, one can argue that it is best to flatten the curve only to the point that the health care system is barely able to cope. This solution only works if-and-only-if one can catch this coronavirus once and develops immunity. In the case of COVID-19, herd immunity may need to be in the 80% to 85% range. WHO warns that few have developed antibodies to COVID-19. At this point, herd immunity does not look like an option although there is now a discussion of whether T-Cells play a part in immunity [which means one might have immunity without antibodies]
- Older population countries will have a higher death rate.
- There are at least 8 strains of the coronavirus. New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States.
- Each publication uses different cutoff times for its coronavirus statistics. Our data uses 11:00 am London time. Also, there is an unexplained variation in the total numbers both globally and in the U.S.
What we do not know about the coronavirus [actually there is little scientifically proven information]. Most of our knowledge is anecdotal, from studies with limited subjects, or from studies without peer review.
- How many people have been infected as many do not show symptoms?
- Masks do work.
- Do we develop lasting immunity to the coronavirus? Another coronavirus – the simple cold – does not develop long term immunity.
- To what degree do people who never develop symptoms contribute to transmission? Research early in the pandemic suggested that the rate of asymptomatic infections could be as high as 81%. But a meta-analysis, which included 13 studies involving 21,708 people, calculated the rate of asymptomatic presentation to be 17%.
- The accuracy of rapid testing is questioned – and the more accurate test results are not being given in a timely manner.
- Can children widely spread coronavirus? [current thinking is that they are a minor source of the pandemic spread]
- Why have some places avoided big coronavirus outbreaks – and others hit hard?
- Air conditioning contributes to the pandemic spread.
- Outdoor activities seem to be a lower risk than indoor activities.
- It seems a vaccine will be available before the end of the year – the question is how effective it will be in the general population AND how long immunity will last.
- Will other medical treatments for Covid-19 ease symptoms and reduce deaths? So far only two drugs (remdesivir and Regeneron) are approved for treatment.
- A current scientific understanding of the way the coronavirus works can be found [here].
Heavy breakouts of coronavirus have hit farm workers. Farmworkers are essential to the food supply. They cannot shelter at home. Consider:
- they have high rates of respiratory disease [occupational hazard]
- they travel on crowded buses chartered by their employers
- few have health insurance
- they cannot social distance and live two to four to a room – and they eat together
- some reports say half are undocumented
- they are low paid and cannot afford not to work – so they will go to work sick
- they do not have access to sanitation when working
- a coronavirus outbreak among farmworkers can potentially shutter entire farm
The bottom line is that COVID-19 so far has been shown to be much more deadly than the data on the flu. Using CDC data, the flu has a mortality rate between 0.06 % and 0.11 % Vs. the coronavirus which to date has a mortality rate of 4 % [the 4% is the average of overall statistics – however in the last few months it has been hovering around 1.0%] – which makes it between 10 and 80 times more deadly. The reason for ranges:
Because influenza surveillance does not capture all cases of flu that occur in the U.S., CDC provides these estimated ranges to better reflect the larger burden of influenza.
There will be a commission set up after this pandemic ends to find fault [it is easy to find fault when a once-in-a-lifetime event occurs] and to produce recommendations for the next time a pandemic happens. Those that hate President Trump will conclude the virus is his fault.
Resources:
- Get the latest public health information from CDC: https://www.coronavirus.gov .
- Get the latest research from NIH: https://www.nih.gov/coronavirus.
- Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/.
- List of studies: https://icite.od.nih.gov/covid19/search/#search:searchId=5ee124ed70bb967c49672dad
include(“/home/aleta/public_html/files/ad_openx.htm”); ?>